Phospho-STAT2 (Y631) Antibody is a polyclonal antibody developed to specifically recognize STAT2 protein only when phosphorylated at the tyrosine 631 residue. This site-specific recognition capability makes it invaluable for studying signal transduction mechanisms involving STAT2 activation. The antibody is derived from rabbit hosts and demonstrates high specificity with no cross-reactivity with other proteins or non-phosphorylated STAT2 .
These antibodies are typically produced by immunizing rabbits with synthetic peptides derived from human STAT2 protein sequences surrounding the phosphorylation site of tyrosine 631. The resulting antiserum undergoes affinity purification using epitope-specific immunogens to ensure high specificity and reduced background noise in experimental applications. The amino acid range covered by the immunogen typically spans residues 597-646 or 570-650, depending on the manufacturer .
The physical and biochemical properties of commercially available Phospho-STAT2 (Y631) antibodies include liquid formulations in phosphate-buffered saline (PBS) containing preservatives and stabilizers such as glycerol, bovine serum albumin (BSA), and sodium azide. The concentration is typically standardized at 1 mg/ml, making it convenient for laboratory use across various applications .
Phospho-STAT2 (Y631) Antibody has been validated for multiple experimental applications, making it a versatile tool in molecular and cellular biology research. Each application requires specific optimization conditions to achieve reliable and reproducible results.
The antibody has been rigorously tested and validated for several experimental techniques, with recommended dilution factors established for optimal performance.
| Application | Recommended Dilution |
|---|---|
| Enzyme-Linked ImmunoSorbent Assay (ELISA) | 1:40000 |
| Immunohistochemistry (IHC) | 1:100-1:300 |
| Immunofluorescence (IF) | Validated (dilution may vary by manufacturer) |
These recommended dilutions serve as starting points for assay optimization. The actual working concentration may vary depending on specific experimental conditions, sample types, and detection methods employed. Researchers are advised to perform titration experiments to determine the optimal antibody concentration for their specific applications .
When working with Phospho-STAT2 (Y631) Antibody, several experimental considerations should be taken into account to ensure reliable results. The phosphorylation state of proteins can be labile and sensitive to sample preparation methods. Therefore, proper sample handling, including the use of phosphatase inhibitors during protein extraction, is essential to preserve the phosphorylation status of STAT2 at tyrosine 631.
For immunohistochemistry applications, appropriate antigen retrieval methods may be necessary to expose the phospho-epitope. The choice between heat-induced epitope retrieval (HIER) and enzymatic antigen retrieval should be empirically determined for each tissue type and fixation method. Additionally, blocking endogenous peroxidase activity and preventing non-specific binding are critical steps to minimize background staining and increase the signal-to-noise ratio .
In ELISA applications, the extraordinarily high dilution factor (1:40000) suggested for some commercial variants of this antibody indicates its high sensitivity and affinity for the phosphorylated epitope. This high sensitivity makes it particularly valuable for quantitative detection of phosphorylated STAT2 in complex biological samples .
Understanding the biological significance of STAT2 and specifically the Y631 phosphorylation site provides important context for the utility of Phospho-STAT2 (Y631) Antibody in research applications. This knowledge helps researchers interpret experimental results and design appropriate studies.
STAT2 is a critical component of the interferon signaling pathway, functioning as a signal transducer and transcription factor. As a member of the STAT protein family, STAT2 plays a pivotal role in mediating cellular responses to cytokines and growth factors. The protein has a molecular weight of approximately 113 kDa and contains several functional domains including an SH2 domain, a DNA-binding domain, and transactivation domains .
In response to interferons (IFNs), particularly type I interferons like IFN-α and IFN-β, STAT2 becomes activated through phosphorylation. This activation prompts STAT2 to form a heterotrimeric complex with STAT1 and interferon regulatory factor 9 (IRF9, also known as p48 or ISGF3G). This complex, known as Interferon-Stimulated Gene Factor 3 (ISGF3), translocates to the nucleus where it binds to specific DNA sequences called Interferon-Stimulated Response Elements (ISREs) to initiate transcription of interferon-stimulated genes (ISGs) .
Unlike other STAT family members, STAT2 lacks direct DNA-binding capability. Instead, within the ISGF3 complex, STAT2 functions primarily as a transactivator, while STAT1 and IRF9 provide the DNA-binding functionality. This unique characteristic distinguishes STAT2 from other members of the STAT family and highlights its specialized role in interferon signaling .
The phosphorylation of STAT2 at tyrosine 631 (Y631) represents a critical regulatory mechanism in the interferon signaling pathway. This specific phosphorylation event is typically catalyzed by Janus kinases (JAKs) that are associated with interferon receptors. Upon interferon binding to its receptor, receptor-associated JAKs become activated and phosphorylate STAT2 at Y631, which is essential for subsequent STAT2 activation and function.
Y631 phosphorylation facilitates the interaction between STAT2 and STAT1, promoting heterodimer formation and subsequent assembly of the ISGF3 complex. This phosphorylation-dependent complex formation is a prerequisite for nuclear translocation and transcriptional regulation of interferon-responsive genes. Consequently, monitoring the phosphorylation status of STAT2 at Y631 using Phospho-STAT2 (Y631) Antibody provides valuable insights into the activation state of the interferon signaling pathway .
Phospho-STAT2 (Y631) Antibody has significant applications in various research fields, particularly in studies involving immune responses, viral infections, and inflammatory conditions. Its ability to specifically detect activated STAT2 makes it an invaluable tool for understanding signaling mechanisms and disease processes.
In immunological research, this antibody allows scientists to monitor interferon signaling pathways that are critical for host defense against pathogens. By detecting phosphorylated STAT2, researchers can assess the activation status of the interferon response in various experimental conditions, including viral infections, autoimmune diseases, and inflammatory disorders.
The interferon pathway, in which STAT2 plays a crucial role, represents the first line of defense against viral infections. Many viruses have evolved mechanisms to inhibit this pathway, often targeting STAT2 function or its phosphorylation. Phospho-STAT2 (Y631) Antibody enables researchers to investigate these viral evasion strategies and understand how they impact interferon signaling and antiviral immunity .
Additionally, this antibody can be utilized to evaluate the efficacy of therapeutic agents designed to modulate the interferon response. Compounds that enhance or inhibit STAT2 phosphorylation can be screened and characterized using this antibody, facilitating drug discovery efforts aimed at treating viral infections, inflammatory diseases, and certain cancers where interferon signaling is implicated.
In molecular and cellular biology, Phospho-STAT2 (Y631) Antibody serves as a valuable tool for investigating signal transduction mechanisms. The antibody can be employed to track the spatiotemporal dynamics of STAT2 activation following stimulation with interferons or other cytokines, providing insights into the kinetics and regulation of this signaling pathway.
Furthermore, this antibody facilitates the study of protein-protein interactions involving phosphorylated STAT2. Co-immunoprecipitation experiments using Phospho-STAT2 (Y631) Antibody can identify novel interaction partners that specifically recognize the phosphorylated form of STAT2, expanding our understanding of the molecular mechanisms underlying interferon signaling.
The antibody also supports research on post-translational modifications beyond phosphorylation. The crosstalk between different modifications (such as phosphorylation, ubiquitination, SUMOylation, and acetylation) in regulating STAT2 function can be investigated using this antibody in combination with other modification-specific antibodies .
Quality control and validation procedures are essential aspects of antibody production and characterization, ensuring the reliability and reproducibility of experimental results obtained with Phospho-STAT2 (Y631) Antibody.
Commercial suppliers of Phospho-STAT2 (Y631) Antibody implement rigorous validation protocols to confirm the specificity and sensitivity of their products. These validation procedures typically include multiple experimental approaches to verify that the antibody specifically recognizes phosphorylated STAT2 at tyrosine 631 without cross-reactivity to non-phosphorylated STAT2 or other phosphorylated proteins.
Validation methods commonly include Western blotting/immunoblotting with positive control samples (cells treated with interferon to induce STAT2 phosphorylation) and negative control samples (untreated cells or cells treated with phosphatase inhibitors). Additional validation approaches may involve immunohistochemistry, immunofluorescence, and ELISA using known positive and negative samples. Some manufacturers also perform phosphopeptide competition assays, where the antibody is pre-incubated with phosphorylated and non-phosphorylated peptides to confirm specificity for the phosphorylated form .
The absence of cross-reactivity with other proteins is an important quality attribute of Phospho-STAT2 (Y631) Antibody. Manufacturers verify this by testing the antibody against a panel of cell lysates or tissue samples expressing various proteins that might potentially cross-react with the antibody. The documented lack of cross-reactivity enhances the reliability of experimental results obtained with this antibody .
The performance characteristics of Phospho-STAT2 (Y631) Antibody, including sensitivity, specificity, and reproducibility, determine its utility in various research applications. High sensitivity enables the detection of low levels of phosphorylated STAT2, which is particularly important when studying early events in signaling cascades or samples with limited amounts of target protein.
Specificity for the phosphorylated form of STAT2 is achieved through careful design of the immunogen and thorough purification procedures. The antibody specifically recognizes STAT2 when phosphorylated at tyrosine 631, without binding to non-phosphorylated STAT2 or other phosphorylated proteins. This high specificity minimizes false positive results and ensures accurate interpretation of experimental data .
Batch-to-batch reproducibility is maintained through standardized production processes and quality control measures. Each lot of antibody undergoes testing to verify consistent performance across multiple applications, ensuring that researchers can obtain reliable and reproducible results regardless of which batch they use .
STAT2 is a 113kDa member of the Signal Transducer and Activator of Transcription family that plays a critical role in type I interferon (IFN) signaling. Following IFN receptor activation, STAT2 is phosphorylated, dimerizes with STAT1, and partners with IRF9 to form the ISGF3 complex that drives transcription of interferon-stimulated genes .
The Y631 residue is part of a conserved motif (PYTK) consisting of proline 630, tyrosine 631, threonine 632, and lysine 633 that regulates STAT protein function . Interestingly, while Y631 itself is not phosphorylated, it plays a critical regulatory role in STAT signaling. Mutation studies have shown that converting Y631 to phenylalanine (Y631F) prolongs STAT1 activation and ISGF3 signaling by decreasing STAT1 dephosphorylation, making this a key regulatory site for interferon response duration .
Phospho-STAT2 (Y631) antibodies can be utilized in multiple experimental applications:
These antibodies are specifically designed to detect endogenous levels of STAT2 protein only when phosphorylated at Y631, providing researchers with a tool to study this regulatory modification .
These two phosphorylation sites serve distinct functions in STAT2 signaling:
Y690: The primary tyrosine phosphorylation site in STAT2, phosphorylated by JAK1/TYK2 kinases following interferon receptor activation. This phosphorylation is essential for STAT2 activation, dimerization with STAT1, and formation of the ISGF3 complex .
Y631: Not directly phosphorylated but plays a regulatory role. The Y631F mutation prolongs STAT1 activation by decreasing dephosphorylation rates . It functions as part of the PYTK motif that modulates the duration and intensity of interferon signaling.
When designing experiments, researchers should carefully select antibodies specific to the phosphorylation site relevant to their research question.
Commercially available Phospho-STAT2 (Y631) antibodies typically demonstrate reactivity with:
Some antibodies may have predicted cross-reactivity with additional species such as pig, bovine, horse, and Xenopus . When planning experiments with non-standard model organisms, researchers should verify reactivity through pilot studies.
The PYTK motif (P630-Y631-T632-K633) contains two critical regulatory residues with opposing effects on STAT2 signaling:
P630 (Proline 630):
Mutation to leucine (P630L) reduces ISGF3 signaling by impairing STAT2 tyrosine phosphorylation
P630L mutation abrogates IFN-α induced apoptosis
This mutation was found to emerge under IFN-α selection pressure
Y631 (Tyrosine 631):
Y631F mutation prolongs STAT1 activation and ISGF3 signaling
This effect occurs through decreased STAT1 dephosphorylation
Y631F promotes the apoptotic effects of IFN-α, opposite to P630L
The proximity and opposing effects of these mutations suggest that the P630-Y631 region forms a critical structural motif influencing both activation and deactivation phases of STAT2 signaling. The proline at position 630 likely creates a specific conformation important for proper STAT2 phosphorylation, while Y631 appears to be involved in regulating signal termination .
STAT2 contains multiple phosphorylation sites that work in concert to regulate interferon signaling:
The S287 site is particularly interesting as a novel regulatory serine residue. When S287 is mutated to alanine (preventing phosphorylation), it generates a gain-of-function STAT2 that enhances IFN-α effects, including:
Increased cell growth inhibition
Prolonged protection against vesicular stomatitis virus infection
Enhanced transcriptional responses
Conversely, the phosphomimetic S287D mutation dramatically impairs STAT2 transcriptional activity and reduces nuclear translocation .
Rigorous validation is critical for phospho-specific antibodies. Researchers should implement the following methodological approaches:
Positive and Negative Controls:
Positive: Cells treated with type I interferons (500-1000 U/mL IFN-α/β for 20-30 minutes)
Negative: Untreated cells or cells pre-treated with JAK inhibitors
Peptide Competition Assay:
Genetic Approaches:
Compare signal in STAT2-knockout cells (e.g., U6A cell line) reconstituted with wild-type vs. mutant STAT2
Y631F mutant expression should alter signaling dynamics compared to wild-type
Phosphatase Treatment:
Treat one sample of lysate with lambda phosphatase
Compare signal between treated and untreated samples
Signal Specificity Controls:
Test for cross-reactivity with other phosphorylated STAT proteins
Verify antibody doesn't recognize other phospho-tyrosine proteins
Proper validation ensures reliable results and prevents misinterpretation of experimental data.
Optimizing experimental conditions is essential for robust detection of STAT2 phosphorylation:
Stimulation Parameters:
Type I interferons: 500-1000 U/mL for most cell types
Optimal stimulation time: 20-30 minutes for peak phosphorylation
Serum starvation (overnight) enhances signal-to-noise ratio
Cell Type-Specific Considerations:
Western Blot Optimization:
Load 30-50μg total protein per lane
Use PVDF membrane (preferred over nitrocellulose for phospho-proteins)
Block in 5% BSA (not milk, which contains phospho-proteins)
Primary antibody dilution: 1:1000 to 1:2000, incubate overnight at 4°C
Immunofluorescence/IHC Considerations:
Fixation: 4% paraformaldehyde (10 min) followed by methanol permeabilization
Antibody dilution: 1:50 to 1:200 range
Include antigen retrieval for paraffin sections (Tris-EDTA, pH 9.0)
For comprehensive analysis of interferon signaling networks:
Multiplexed Western Blotting:
Sequential immunoblotting with stripping between antibodies
Analyze multiple parameters on the same membrane:
Phospho-STAT2 (Y631)
Phospho-STAT2 (Y690)
Total STAT2
Phospho-STAT1 (Y701)
Phospho-JAK1/TYK2
Multi-Color Flow Cytometry:
Kinetic Analysis:
Perform time-course experiments (5, 15, 30, 60, 120 min post-stimulation)
Measure multiple phosphorylation events at each timepoint
Compare wild-type vs. Y631F STAT2 to reveal regulatory mechanisms
Include phosphatase inhibitors at different timepoints to assess dephosphorylation kinetics
Genetic Approaches:
Compare cells expressing STAT2 mutations:
Y631F mutation
P630L mutation
Y690F mutation
S287A/D mutations
Analyze effects on multiple pathway components simultaneously
Proper experimental controls are essential for interpreting results with phospho-specific antibodies:
Positive Controls:
Cell lysates from interferon-stimulated cells (e.g., Daudi cells treated with 500 U/mL IFN-α for 20 minutes)
Positive control lysates provided by antibody manufacturers
Negative Controls:
Unstimulated cell lysates
Lysates from cells pre-treated with JAK inhibitors (e.g., Ruxolitinib, Tofacitinib)
Phosphatase-treated positive control lysates
Specificity Controls:
Peptide competition with phospho-peptide vs. non-phospho-peptide
Isotype control antibodies at equivalent concentration
Genetic Controls:
The inclusion of these controls helps validate antibody specificity and ensures accurate interpretation of experimental results.
When working with samples where phospho-STAT2 is present at low abundance:
Sample Enrichment Techniques:
Immunoprecipitation with total STAT2 antibody followed by phospho-STAT2 detection
Phospho-tyrosine enrichment using anti-pTyr antibodies
Subcellular fractionation to concentrate nuclear fractions where activated STAT2 resides
Signal Amplification Methods:
Enhanced chemiluminescence (ECL) substrates with extended sensitivity
Tyramide signal amplification for immunohistochemistry
Biotin-streptavidin amplification systems
Optimization of Blocking and Antibody Conditions:
Extend primary antibody incubation time (overnight at 4°C)
Test different blocking agents (BSA, commercial blockers, normal serum)
Optimize antibody dilution through titration experiments
Technical Considerations:
Use fresh phosphatase inhibitors in all buffers
Process samples rapidly to prevent dephosphorylation
Consider using PVDF membranes with smaller pore size (0.2μm) for Western blotting
Increase exposure time incrementally while monitoring background
These methodological refinements can significantly improve detection sensitivity while maintaining specificity.